Instead of asking questions do some DD. Here is for the start:
AMDA is the only firm using a silicon nitride technology platform for medical applications. Silicon nitride bio-material promotes bone growth, hardness, and strength; resists wear; and has anti-infective properties that AMDA believes other commonly used bio-materials, like polyetheretherketone, cannot match. The firm also offers complementary non-silicon nitride spinal fusion products, which accounted for approximately 70% of AMDA's revenues in calendar 2011 and 2012. AMDA operates a 30,000 square foot manufacturing facility in Salt Lake City.
AMDA offers the following figures in its S-1 balance sheet for the nine months ending September 30, 2013:
Net Loss: ($8,948,291.00)
Total Assets: $35,569,104.00
Total Liabilities: $28,009,394.00
Stockholders' Equity: ($153,896,102.00)
Amedica is a simple story. If you believe Silicon Nitride is the next "bio-material" solving the infection issues surrounding titanium implants, the stock will be acquired for a meaningful amount of money. The looses are attributed to core research in what is already approved by the FDA in spine implants. This is a biomaterial, technology play.
One of three. One, sales are up, two, some sorft of A&M with getting new hospital based product, three, informal buyout talks.....